Amgen: EMA recommends marketing approval for Amgen Europe's Tepezza to treat adults with moderate to severe thyroid eye disease
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe
Read full article »
Amgen is a California-based multinational biopharmaceutical company that develops human therapeutics for the treatment of diseases including cancer and cardiovascular.
Read more